TC BioPharm (Holdings) plc American Depositary Shares
TCBP
TCBP was delisted on the 21st of March, 2025.
3 hedge funds and large institutions have $207K invested in TC BioPharm (Holdings) plc American Depositary Shares in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
200% more funds holding
Funds holding: 1 → 3 (+2)
36% less capital invested
Capital invested by funds: $324K → $207K (-$116K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$167K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$27.8K |
| 3 |
SFG
Steward Financial Group
Colleyville,
Texas
|
+$13.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$5.36K |
TCBP Hedge Fund Activity: Q1 2023 in Review
3 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in TC BioPharm (Holdings) plc American Depositary Shares (TCBP) for Q1 2023, worth a combined $207K — down 36% from $324K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new TCBP positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, adding an estimated $167K. The largest seller was UBS Group, cutting an estimated $5.36K.
- 3 institutional investors held TC BioPharm (Holdings) plc American Depositary Shares (TCBP) as of Q1 2023, up from 1 in Q4 2022.
- Funds reported $207K of TC BioPharm (Holdings) plc American Depositary Shares stock for Q1 2023, down 36% quarter-over-quarter.
- 2 funds opened new TC BioPharm (Holdings) plc American Depositary Shares positions in Q1 2023 and 0 closed out, a net change of +2 holders.
- The largest TC BioPharm (Holdings) plc American Depositary Shares buyer in Q1 2023 was Armistice Capital, an estimated $167K added.
- The largest TC BioPharm (Holdings) plc American Depositary Shares seller in Q1 2023 was UBS Group, an estimated $5.36K sold.
Based on aggregated 13F filings for Q1 2023.